Another NZ Public Healthcare Providers Adopts Cxbladder

ANOTHER OF NEW ZEALAND'S PUBLIC HEALTHCARE PROVIDERS, HAUORA TAIRAWHITI, ADOPTS CXBLADDER Gisborne's Hauora Tairawhiti (Tairawhiti District Health Board) to Implement Cxbladder Testing for Urology Referrals Cancer diagnostics company, Pacific Edge (NZX: PEB), will this month commence Cxbladder testing for Hauora Tairawhiti (TDHB) urology patients undergoing investigation of haematuria (blood in the urine) for diagnosis and post-treatment surveillance of bladder cancer at Gisborne hospital. Hauora Tairawhiti, New Zealand's eastern-most DHB includes many of New Zealand's most remote rural communities. Head of urology, Mr John Boulton noted that, "Cxbladder testing will help identify a number of patients referred to urology, for whom an invasive cystoscopy can be safely avoided, while providing patients with the reassurance that they do not have bladder cancer. Aside from the patient benefits, this will also contribute to a more efficient urology service for the region." Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: "The commercial adoption by Hauora Tairawhiti adds to the growing list of public healthcare providers signing up for Cxbladder. Timely, accurate diagnosis, access and ease of use are important considerations in urologic health, and are the hallmarks of Cxbladder. "By including Cxbladder within the urology workup in regional settings such as New Zealand's East Coast, many patients can get the peace of mind that they don't have bladder cancer from our easy-to-use urine test, thereby avoiding a cystoscopy and the need to travel long distances to the hospital." ENDS For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 OVERVIEW www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Triage, Detect and Monitor are available through the company's dedicated CLIA-certified laboratories for customers in New Zealand, Australia, Singapore and the USA. Cxbladder Resolve launched in New Zealand in December 2016. ABOUT Cxbladder Triage www.cxbladder.com Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma. ABOUT Cxbladder Detect www.cxbladder.com Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. ABOUT Cxbladder Monitor www.cxbladder.com Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer. ABOUT Cxbladder Resolve www.cxbladder.com Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient characteristics for the identification of patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings. Refer to www.cxbladder.com for more information. End CA:00322309 For:PEB Type:MKTUPDTE Time:2018-08-16 09:29:42